Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on the research and development of novel therapeutics targeting retinal degenerative eye diseases and metabolic disorders. The company's pipeline is built on its RBP4 (Retinol Binding Protein 4) intellectual property portfolio, with a primary focus on unmet medical needs in blindness, liver disease, and diabetes. Its lead candidate, tinlarebant (LBS-008), is an oral therapy intended to reduce toxin accumulation in the eye, currently in Phase 3 trials for geographic atrophy associated with dry age-related macular degeneration and Stargardt disease. The company is also developing LBS-009 for non-alcoholic fatty liver disease and type 2 diabetes. Belite Bio operates through subsidiaries including Belite Bio Holdings Corp, Belite Bio, LLC, RBP4 Pty Ltd, Belite Bio (HK) Limited, Belite Bio (Shanghai) Limited, Belite Bio (Taiwan) Inc, Belite Bio (Swiss) AG, and Belite Bio Japan Inc. The company was formerly known as Lin BioScience Co., Ltd and was incorporated in 2018.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage belitebio.com
Sector Healthcare IR page investors.belitebio.com
Tags
retinal degenerative diseases, geographic atrophy, stargardt disease, oral therapeutics, liver disease, type 2 diabetes, clinical stage, r&d, tinlarebant, LBS-008, LBS-009, RBP4, Belite Bio Holdings Corp, Belite Bio LLC, RBP4 Pty Ltd, Belite Bio (HK) Limited, Belite Bio (Shanghai) Limited, Belite Bio (Taiwan) Inc, Belite Bio (Swiss) AG, Belite Bio Japan Inc, DRAGON, DRAGON II, PHOENIX
Press page —

Metrics

Valuation  
Market cap $ 6.567B
Market cap (USD) $ 6.567B
P/E -72.26
PEG —
P/BV 8.52
P/S —
P/OCF -177.54
P/FCF -177.20
Dividend yield —
Turnover / mcap —
Returns  
ROE -16.9%
ROI -18.6%
ROIC -15.1%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 39
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Assets 780.556M 152.132M 94.642M 44.273M 18.348M
Net profit -77.611M -36.144M -31.632M -12.648M -9.666M
Free cash flow -37.059M -29.35M -29.9M -11.852M -7.548M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 159.96 63.1 45.75 30.6 —
Price performance 12m 1.54 0.38 0.5 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 941,000 866,000 886,000 537,000 429,000
Cash and deposits (USD) 2.02M 25.6M 17.3M 42.1M 88.2M 31.7M 353M
Intangible assets (USD) — — — — — 31,000 19,000
Right-of-use assets (USD) — — 941,000 806,000 811,000 521,000 433,000
Cash flow detail
Operating cash flow (USD) — -4.44M -7.47M -11.5M -29.8M -29.2M -37M
Purchases of property, plant and equipment (USD) — — -74,000 -394,000 -63,000 -116,000 -71,000
Purchases of intangible assets (USD) — — — — — -35,000 —
Interest paid (cash effect) (USD) — -19,000 — -16,000 — — -1,000
Income taxes paid (cash effect) (USD) — — — — -9,000 -6,000 —
Share-based compensation (USD) — 1.36M 1.53M 1.48M 3.82M 8.99M 38.9M
Free cash flow (OCF - PPE - intangibles) (USD) — — -7.55M -11.9M -29.9M -29.4M -37.1M
Income detail
Research and development expense (USD) — 3.69M 7.42M 8.87M 24.8M 29.9M 45.4M
↳ 5y CAGR +65.2%
Total comprehensive income (USD) — -5.75M -9.82M -12.8M -31.6M -36.4M -77.5M
Comprehensive income to owners (USD) — -5.75M -9.82M -12.8M -31.6M -36.4M -77.5M
Reported Mar 31, 2023 Mar 31, 2023 Mar 31, 2023 Mar 31, 2023 Mar 12, 2024 Mar 17, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

· New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027

· Company has been informed by the FDA that it will not convene an advisory committee meeting to discuss the NDA for tinlarebant in STGD1

· Submitted NDA for tinlarebant to Japan’s Ministry of Health, Labour and Welfare under Sakigake designation (J-NDA)

· Submitted Marketing Authorization Applications for tinlarebant in Singapore, the United Kingdom, and Switzerland via the Access Consortium pathway

· Company uplisted to the Nasdaq Global Select Market

· Conference call and webcast on Thursday, November 12, 2026, at 4:30 p.m. ET

SAN DIEGO, November 12, 2026 - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

SAN DIEGO, October 19, 2026 (GLOBE NEWSWIRE) - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market will commence at the open of market on October 19, 2026, under the Company’s existing ticker symbol “BLTE.”

The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers. The uplisting to this Market reflects the Company’s compliance with the Nasdaq Global Select Market’s more stringent financial and liquidity standards, as well as the Company’s continued progress in strengthening its financial profile and capital markets presence. The transition to this highest tier of the Nasdaq market is expected to enhance the Company’s visibility among institutional investors, improve liquidity, and broaden market recognition.

About Tinlarebant (a/k/a LBS-008) Bull 0 Bear 0 Other

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.

Prompts

Belite Bio, Inc (ticker BLTE), listed in United States.

ETFs Holding Belite Bio, Inc

ETF Weight in ETF Shares Market value As of
EHLS 0.39% 1,307 $ 212.466K Nov 17, 2026
APIE 0.06% 4,158 $ 647.442K Aug 31, 2026
MSSM 0.01% 423 $ 65.865K Aug 31, 2026